Overview
Astressin-B is a long-acting peptide antagonist of corticotropin-releasing hormone receptors, with molecular mass about 4,044 g/mol and formula C183H305N47O55. It grew out of CRF peptide research from the Salk Institute and related stress-biology programs. Its most widely cited public finding is hair regrowth in a mouse model of chronic CRF overexpression, not a human alopecia trial.
The peptide targets CRF1 and CRF2 receptor signaling. CRF coordinates the hypothalamic-pituitary-adrenal stress response and also affects gut motility, immune signaling, skin biology, and behavior. Blocking CRF receptors can therefore produce broad physiological effects. That breadth is scientifically interesting but also makes casual use risky because stress-axis signaling is not a simple on/off switch.
Astressin-B is not FDA-approved for hair loss, anxiety, cortisol control, or any human indication. Published work is mainly animal or mechanistic peptide pharmacology. The mouse alopecia result was striking, but it involved genetically modified CRF-overexpressing mice, short peripheral injections, and a disease model that does not equal androgenetic alopecia or alopecia areata in humans.
This guide explains the CRF receptor mechanism, what the hair-regrowth data actually showed, what safety gaps remain, and why practical claims about dosing, cortisol lowering, or human hair regrowth should be framed as speculative.
Quick facts
- Mechanism
- Nonselective CRF1/CRF2 peptide antagonist affecting stress-axis signaling
- Primary use
- Stress Response Research
- Evidence
- limited
- FDA
- Not approved
- Route
- Intraperitoneal or subcutaneous injection in animal studies
- Typical results
- Hair regrowth in CRF-overexpressing mice after short peripheral dosing
Chemical information
Astressin-B is a large synthetic peptide antagonist derived from CRF-family peptide engineering, with molecular mass about 4,044 g/mol. Its constrained sequence was designed to bind CRF receptors while reducing agonist activity.
How Astressin-B works
Astressin-B blocks CRF receptor signaling, especially peripheral CRF1 and CRF2 activity depending on model and route. CRF normally drives ACTH release, stress behavior, gut changes, and inflammatory crosstalk. By reducing receptor activation, astressin-B can alter HPA-axis output and local tissue responses. Its effects depend heavily on species, route, dose, and whether the target biology is peripheral or central.
In CRF-overexpressing mice, peripheral astressin-B for five days triggered pigmentation and hair regrowth that persisted for months in many animals. The authors interpreted this as resetting a CRF-linked hair-cycle switch, moving follicles from an atrophic or resting state toward anagen growth. Importantly, the effect did not simply normalize all systemic Cushing-like features, so local skin and follicle CRF signaling may be central.
Astressin-B belongs to a family of engineered CRF peptide antagonists designed to improve potency and duration versus earlier fragments. These peptides can block receptor activation without easily crossing the blood-brain barrier when given peripherally, which helps researchers separate peripheral from central CRF effects. That does not make them benign: CRF signaling also helps coordinate immune, endocrine, and autonomic adaptation.
Human translation is uncertain. Hair loss in people can be androgen-driven, autoimmune, inflammatory, drug-induced, nutritional, endocrine, or stress-associated. A CRF-overexpression mouse result is not enough to define which human subgroup, if any, would respond.
- CRF receptor blockade: Antagonizes CRF1 and CRF2 receptor signaling in research models
- HPA-axis modulation: Can alter ACTH and stress-hormone responses depending on route
- Hair-cycle signaling: Reversed alopecia in CRF-overexpressing mice by promoting anagen-like regrowth
- Peripheral bias: Peripheral dosing may emphasize noncentral CRF pathways
- Gut-brain relevance: CRF receptors regulate stress-linked gastrointestinal responses
- Translation gap: No controlled human hair-loss efficacy data support routine use
Pharmacokinetics
Human pharmacokinetic data for astressin-B are not established. Animal studies support longer action than earlier CRF peptide antagonists, but no reliable human half-life, bioavailability, or dosing interval should be inferred.
| Parameter | Value | Significance |
|---|---|---|
| Human PK | Not established | No approved dosing interval or half-life exists |
| Animal route | IP or SC injection | Hair-regrowth mouse work used short peripheral dosing |
| Central penetration | Limited by peptide size | Peripheral effects may dominate after systemic injection |
| Metabolism | Proteolytic peptide degradation | Expected breakdown by peptidases |
| Duration | Longer acting than early CRF antagonists in models | Still not a validated human PK value |
| Target engagement | CRF1/CRF2 receptor blockade | Effects depend on receptor distribution and disease model |
Dosing & administration
No FDA-approved astressin-B dose exists. The commonly cited mouse alopecia study used 5 mcg per mouse once daily for five days by peripheral injection. That is an animal protocol in genetically modified mice and should not be converted into a human hair-loss regimen.
Because CRF signaling touches endocrine, immune, autonomic, and gastrointestinal systems, any translational study would require hormone monitoring, stress-response endpoints, adverse-event tracking, and clear inclusion criteria. Cosmetic endpoints alone would be too narrow.
For peptide users, the practical takeaway is restraint: astressin-B is a research tool for CRF biology, not a validated cortisol-control or hair-growth product. Unknown purity and route amplify the uncertainty.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Astressin-B has intriguing animal data but a major human safety gap. People with adrenal, pituitary, psychiatric, autoimmune, cardiovascular, or pregnancy-related concerns should avoid unsupervised exposure to CRF-pathway antagonists.
Common
- • Injection site irritation
- • Fatigue or altered stress response by mechanism
- • Gastrointestinal motility changes
- • Headache or malaise by class uncertainty
- • Transient appetite or weight changes in animal models
- • No noticeable cosmetic effect
Serious / potential risks
- • Unknown endocrine consequences with repeated exposure
- • Potential adrenal-axis disruption in vulnerable users
- • Immune or inflammatory effects from CRF pathway modulation
- • Unsafe use in pregnancy or endocrine disease
- • Contamination or dosing error from research-grade material
Drug interactions
Formal drug-interaction studies are lacking; concerns are based on CRF pathway biology and endocrine overlap.
| Medication | Interaction | Recommendation |
|---|---|---|
| Glucocorticoids | May complicate HPA-axis interpretation | Avoid unsupervised combination |
| ACTH or adrenal testing agents | May affect stress-axis study results | Disclose use before endocrine testing |
| Psychiatric medications | Stress-axis modulation may confound symptoms | Medical supervision required |
| Immunosuppressants | CRF pathways interact with immune signaling | Avoid uncontrolled stacking |
| Hair-loss therapies | May confound response attribution | Do not assume additive benefit |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide suppliers | $150-$500+ per vial | Large peptide; cost depends heavily on purity and quantity |
| Custom synthesis | $1,000+ depending on scale | Sequence verification and purity documentation are critical |
| Analytical testing | $200-$600+ per sample | LC-MS and HPLC are important for identity |
The bottom line
Astressin-B is a serious CRF receptor research peptide with striking mouse alopecia data, but it is not a proven human hair-loss therapy. The biology is broad, the endocrine implications are meaningful, and human dosing and safety remain undefined.
Best for
- • Researchers studying CRF receptor biology
- • Animal models of stress-axis and skin signaling
- • Mechanistic work on stress-linked hair-cycle changes
Not for
- • Self-treatment of hair loss
- • Casual cortisol suppression
- • Pregnancy, adrenal disease, or pituitary disorders
- • Replacing standard dermatology evaluation
Related compounds
Acetic Acid
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Amino Tadalafil
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
AOD-9604
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
B7-33
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Wang L, Million M, Rivier J, et al.. CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice. PLoS ONE (2011). doi: 10.1371/journal.pone.0016377
- [2] Rivier JE, Rivier CL. Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Frontiers in Neuroendocrinology (2014). doi: 10.1016/j.yfrne.2013.10.006 PMID: 24269930
- [3] Rivier JE, Kirby DA, Lahrichi SL, et al.. Characterization of multisubstituted corticotropin releasing factor peptide antagonists (astressins). Journal of Medicinal Chemistry (2016). PMID: 26789203
- [4] Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981). PMID: 6267699
- [5] Rivier J, Rivier C, Vale W. Potent, long-acting corticotropin-releasing factor receptor antagonists. Proceedings of the National Academy of Sciences (1995).
- [6] Tache Y, Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. Journal of Physiology and Pharmacology (2007). PMID: 18212400